Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Hematol ; 98(3): 355-60, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23955111

ABSTRACT

Patients with X-linked severe combined immunodeficiency (X-SCID) suffer from severe and persistent infections, and usually die early in life unless treated by hematopoietic stem cell transplantation. If a patient has an HLA-identical sibling donor, preparative conditioning is not necessary for T-cell engraftment and B-cell function. However, in the absence of such a donor, long-term reconstitution of full B-cell function is often problematic, leading in many cases to a lifetime requirement for immunoglobulin replacement therapy. Preparative myeloablative conditioning has been shown to improve long-term B-cell function, but may aggravate pre-existing infection and transplant-related toxicity. It is thus important to determine the minimum intensity of conditioning that assures immunoglobulin production. In the present study, we performed reduced-intensity conditioning (RIC), consisting of fludarabine 125 mg/m(2) and melphalan 80 mg/m(2), prior to unrelated umbilical cord blood transplantation (UCBT) for five patients with X-SCID, none of them had an HLA-identical donor. Four patients survived more than 4 years without sequelae, and none required long-term immunoglobulin replacement therapy. One patient succumbed to sepsis in conjunction with severe GVHD. Our result demonstrates that the RIC regimen described above in combination with UCBT is an effective and less toxic conditioning to correct B-cell function in patients with X-SCID.


Subject(s)
Antineoplastic Agents/administration & dosage , B-Lymphocytes/immunology , Cord Blood Stem Cell Transplantation , Melphalan/administration & dosage , Transplantation Conditioning/methods , Vidarabine/analogs & derivatives , X-Linked Combined Immunodeficiency Diseases/immunology , X-Linked Combined Immunodeficiency Diseases/therapy , Female , Graft vs Host Disease/prevention & control , HLA Antigens , Humans , Immunoglobulins/administration & dosage , Infant , Male , Survival Rate , Time Factors , Treatment Outcome , Vidarabine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...